Remepy Reports Strong Clinical Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson's Disease

Double-blind, placebo-controlled randomized study demonstrates significant improvements in motor and non-motor symptoms, as well as mechanistic proof in functional MRI imaging Phase III study planned for H2 2026 is the most advanced drug-software combination program in development The...